Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

44.4K
Overview
44.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Meningococcal B Vaccine to Prevent <i>Neisseria gonorrhoeae</i> Infection.

The New England journal of medicine·2026
Same author

Innate immune responsiveness predicts enhanced cellular immunity and symptomatic disease after controlled human influenza infection.

Nature medicine·2026
Same author

HIV cascade, key indicators, and other epidemiological metrics in Australia (2004-2023): a retrospective analysis.

The Lancet regional health. Western Pacific·2026
Same author

Barriers and Facilitators to Oral HIV Pre-exposure Prophylaxis Use in Australia: A Scoping Review Comparing Findings to Canada, New Zealand, and the United Kingdom.

AIDS and behavior·2026
Same author

A temporal map of B cell diversification mechanisms in mice.

Nature immunology·2026
Same author

The pyrrolidinamide antimalarial drug MMV367 rapidly clears blood-stage <i>Plasmodium falciparum</i> in healthy adults with experimental malaria.

Science translational medicine·2026

Related Experiment Video

Updated: Jun 26, 2025

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

10.7K

Predicting vaccine effectiveness for mpox.

Matthew T Berry1, Shanchita R Khan1, Timothy E Schlub1,2

  • 1Kirby Institute, University of New South Wales, Sydney, NSW, Australia.

Nature Communications
|May 8, 2024
PubMed
Summary

Antibody levels after Modified Vaccinia Ankara (MVA-BN) vaccination correlate with mpox vaccine effectiveness. Delaying the second MVA-BN dose may offer more durable protection, especially during vaccine shortages.

More Related Videos

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors
09:16

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

Published on: October 30, 2016

11.2K
Determination of Vaccine Immunogenicity Using Bovine Monocyte-Derived Dendritic Cells
12:54

Determination of Vaccine Immunogenicity Using Bovine Monocyte-Derived Dendritic Cells

Published on: May 19, 2023

1.9K

Related Experiment Videos

Last Updated: Jun 26, 2025

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

10.7K
A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors
09:16

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

Published on: October 30, 2016

11.2K
Determination of Vaccine Immunogenicity Using Bovine Monocyte-Derived Dendritic Cells
12:54

Determination of Vaccine Immunogenicity Using Bovine Monocyte-Derived Dendritic Cells

Published on: May 19, 2023

1.9K

Area of Science:

  • Immunology
  • Vaccinology
  • Epidemiology

Background:

  • The Modified Vaccinia Ankara vaccine (MVA-BN) was crucial for mpox prevention during the 2022 outbreak.
  • MVA-BN approval relied on immunogenicity and animal models, lacking clinical efficacy data and a validated correlate of protection.
  • No established antibody threshold predicts MVA-BN effectiveness against mpox.

Purpose of the Study:

  • To determine if vaccinia-binding ELISA endpoint titers predict MVA-BN vaccine effectiveness against mpox.
  • To analyze antibody kinetics post-vaccination to predict protection durability and optimal dosing intervals.
  • To provide a quantitative, evidence-based method for assessing mpox vaccine effectiveness using antibody measurements.

Main Methods:

  • Systematic literature search and meta-analysis of available mpox vaccination data.
  • Correlation analysis between vaccinia-binding antibody titers and reported vaccine effectiveness.
  • Modeling of antibody kinetics to predict protection duration and impact of dose spacing.

Main Results:

  • A significant correlation was observed between vaccinia-binding antibody titers and vaccine effectiveness, supporting antibodies as a potential correlate of protection.
  • Analysis of antibody kinetics suggests that delaying the second MVA-BN dose can enhance protection durability.
  • The findings indicate that extended dosing intervals may be advantageous in resource-limited outbreak scenarios.

Conclusions:

  • Vaccinia-binding antibody titers show promise as a predictive correlate of mpox vaccine effectiveness.
  • Optimizing MVA-BN dosing schedules, specifically by delaying the second dose, can improve long-term protection.
  • This study offers a quantitative framework for utilizing antibody data to inform public health strategies for mpox vaccination.